

Genetic and Molecular Testing

MEDICAL POLICY NUMBER: 215

Effective Date: 1/1/2024
Last Review Date: 11/2023
Next Annual Review: 8/2024
COVERAGE CRITERIA ..... 2
POLICY CROSS REFERENCES..... 3
POLICY GUIDELINES..... 4
REGULATORY STATUS..... 6
CLINICAL EVIDENCE AND LITERATURE REVIEW ..... 6
BILLING GUIDELINES AND CODING ..... 10
REFERENCES..... 19
POLICY REVISION HISTORY..... 20

INSTRUCTIONS FOR USE: Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

SCOPE: Providence Health Plan, Providence Health Assurance, and Providence Plan Partners as applicable (referred to individually as "Company" and collectively as "Companies").

## PLAN PRODUCT AND BENEFIT APPLICATION

Commercial

Medicaid/OHP\*

Medicare\*\*

### \*Medicaid/OHP Members

*Oregon*: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

Notice to Medicaid Policy Readers: For comprehensive rules and guidelines pertaining to this policy, readers are advised to consult the Oregon Health Authority. It is essential to ensure full understanding and compliance with the state's regulations and directives. Please refer to OHA's prioritized list for the following coverage guidelines:

Medicaid members must also meet the genetic testing criteria governed by the Oregon Health Plan (OHP) Prioritized List Guideline Notes D1 and D17.

### \*\*Medicare Members

This *Company* policy may be applied to Medicare Plan members only when directed by a separate *Medicare* policy. Note that investigational services are considered “**not medically necessary**” for Medicare members.

## COVERAGE CRITERIA

- I. Genetic and molecular testing (see [Policy Guidelines](#) for some examples) may be considered **medically necessary** when **ALL** of the following criteria (A.-D) are met:
  - A. Genetic Counseling general requirements have been met; **and**
  - B. The individual being tested meets **either** of the following criteria:
    1. The patient is symptomatic, and the clinical presentation is consistent with a known condition; **or**
    2. The individual is asymptomatic and meets **either** of the following criteria:
      - a. Individual has a first-degree blood relative (parent, sibling, or child) diagnosed with a condition **and** the affected relative has not had genetic testing and is unavailable for testing; **or**
      - b. Testing is for a known pathogenic variant confirmed in an affected first-degree blood relative (parent, sibling, or child); **and**
  - C. The condition being tested for is associated with increased morbidity or reduced life-expectancy; **and**
  - D. Clinical utility is established for tests as demonstrated by both of the following:

1. Testing allows for a definitive diagnosis or risk classification when other clinical and/or laboratory tests were inconclusive **or** avoids more invasive diagnostic testing (e.g., muscle biopsy); **and**
2. Testing results will guide decision(s) in clinical management (predictive, diagnostic, prognostic, or therapeutic).

### **Genetic Testing for Nonsyndromic Forms of Hearing Loss**

- II. Comprehensive genetic testing or next generation sequencing for diagnosing hearing loss in children may be considered **medically necessary** in children with bilateral sensorineural hearing loss without syndromic findings if patient also meets all of Criterion I. For members with clinical findings that suggest a specific genetic syndrome, targeted genetic testing should be performed to evaluate for the specific syndrome.
- III. Genetic panel testing or next generation sequencing for diagnosing hearing loss is considered **not medically necessary** in patients with nonsyndromic **unilateral** hearing loss.

### **Hypopituitarism**

- IV. Genetic testing for growth hormone (GH) deficiency, hypopituitarism and/or combined pituitary hormone deficiency may be **medically necessary** in members with GH deficiency and at least one other pituitary hormone deficiency that have met all of Criterion I.

### **Not Medically Necessary Testing**

- V. Genetic and molecular testing may be considered **not medically necessary** when there is sufficient evidence to demonstrate that the testing target or strategy is lacking clinical utility (See [Policy Guidelines](#)).
- VI. Genetic and molecular testing may be considered **not medically necessary** when the criteria above are not met.
- VII. Repeat testing of the same germline genetic content, for the same genetic information, is considered **not medically necessary**.

Link to [Evidence Summary](#)

## **POLICY CROSS REFERENCES**

- [Cardiac Disease Risk Screening](#)
- [Circulating Tumor Cell and DNA Assays for Cancer Management](#)
- [Direct to Consumer and Over the Counter Testing](#)
- [Genetic Counseling](#)
- [Genetic Testing: CADASIL Disease](#)
- [Genetic Testing: Diagnostic Evaluation of Interstitial Lung Disease](#)

- [Genetic Testing: Hereditary Breast and Ovarian Cancer](#)
- [Genetic Testing: Inherited Susceptibility to Colorectal Cancer](#)
- [Genetic Testing: Inherited Thrombophilias](#)
- [Genetic Testing: Myeloproliferative Diseases](#)
- [Genetic Testing: Non-Covered Genetic Panel Tests](#)
- [Genetic Testing: Reproductive Planning and Prenatal Testing](#)
- [Genetic Testing: Thyroid Nodules](#)
- [Genetic Testing: Whole Exome, Whole Genome and Proteogenomic Testing](#)
- [Inflammatory Bowel Disease \(IBD\) Serologic Testing and Therapeutic Monitoring](#)
- [Inflammatory Bowel Disease Measurement of Antibodies to Immunosuppressive Therapies](#)
- [Next Generation Sequencing for Minimal Residual Disease Detection](#)
- [Non-Small Cell Lung Cancer: Molecular Testing for Targeted Therapy](#)
- [Ovarian Cancer: Multimarker Serum Testing](#)
- [Vectra DA Test for Rheumatoid Arthritis](#)

The full Company portfolio of current Medical Policies is available online and can be [accessed here](#).

## POLICY GUIDELINES

### Genetic tests that may be medically necessary

The following tests may be medically necessary if meet policy criteria (not all inclusive):

- Periodic fever syndromes
- Loews-Dietz Syndrome panels including genes *FBN1*, *SMAD2*, *SMAD3*, *TGFB2*, *TGFB3*, *TGFBR1*, and *TGFBR2*
- Familial or hereditary pancreatitis including genes *PRSS1*, *CFTR*, *CTRC*, *SPINK1*, and/or *CASR*

### DOCUMENTATION REQUIREMENTS

In order to determine the clinical utility of a genetic test, the following documentation must be provided at the time of the request. Failure to submit complete documentation may affect the outcome of the review.

- Specific gene, trade or proprietary name of the test, or if a custom-built test, include every gene(s) and/or component of the test
- Name of laboratory where the testing is being conducted or was conducted
- Clinical notes to include the following:
  - Reason (indication) for performing test, including the suspected condition
  - Existing signs and/or symptoms related to reason for current test request
  - Prior test/laboratory results related to reason for current test request
  - Family history, if applicable
  - How results from current test request will impact clinical decision making
- All relevant CPT/HCPCS codes billed

## **DEFINITIONS**

### Clinical Utility

Clinical utility of any genetic test is established by evaluating the following components of the test:

- Eliminates the need for further clinical workup or invasive testing
- Leads to changes in clinical management of the condition that improve outcomes
- Leads to discontinuation of interventions that are unnecessary and/or ineffective
- Leads to initiation of effective medication(s) and/or changes in dosing of a medication that is likely to improve outcomes
- Leads to discontinuation of medications that are ineffective or harmful
- Provides prognostic information not revealed by standard laboratory and/or clinical testing that reclassifies patients into clinically relevant prognostic categories for which there are different treatment strategies

### General Principles of Genetic Testing

All genetic tests must be Food and Drug Administration (FDA)-approved and/or performed in a Clinical Laboratory Improvement Amendments (CLIA)-accredited laboratory.

### Nonsyndromic Hearing Loss

Nonsyndromic hearing loss is a partial or total loss of hearing that is not associated with other signs and symptoms.<sup>1</sup>

### Syndromic Hearing Loss

Syndromic hearing loss occurs with signs and symptoms affecting other parts of the body.<sup>1</sup>

## **BACKGROUND**

A genetic test is the analysis of human deoxyribonucleic acid (DNA), ribonucleic acid (RNA), chromosomes, proteins, and certain metabolites in order to detect heritable disease-related genotypes, mutations, phenotypes, or karyotypes for clinical purposes. Genetic tests may be used to detect newborn or adult genetic disease.<sup>2</sup> The tests should aid in the diagnosis or in the treatment of a disorder, including screening in appropriate populations. Genetic tests should have proven analytical validity along with clinical utility and validity, as evidenced in peer-reviewed literature.

Certain technologies, some of which are new and emerging, allow for testing multiple targets and/or genes at once, or testing in a large scale manner up to entire genomes. While the goal of testing with these broad scope strategies may be increased efficiencies, the outcome of attaining results with no known or unknown clinical utility (variants of uncertain significance) has the potential to cause harm via the uncertainty of the results.<sup>3</sup>

### **Hearing Loss**

Sensorineural hearing loss (SNHL) is hearing loss resulting from damage, disease, or other disorders affecting the inner ear (e.g., cochlea) and/or the auditory nerve (cranial nerve VIII).<sup>4</sup>

This differs from conductive hearing loss that is caused by a problem of the outer or middle ear that interferes with conduction of sound to the inner ear.

## Hypopituitarism

Hypopituitarism refers to decreased secretion of pituitary hormones, which can result from diseases of the pituitary gland or from diseases of the hypothalamus.<sup>5</sup> The latter cause diminished secretion of hypothalamic-releasing hormones, thereby reducing secretion of the corresponding pituitary hormone.

### Combined Pituitary Hormone Deficiency (CPHD) Panel<sup>6</sup>

*Combined pituitary hormone deficiency* (CPHD) is a condition characterized by impaired production of growth hormone and at least one of the other 5 hormones produced by the anterior pituitary. The prevalence of CPHD is estimated to be 1 in 8,000 individuals, and approximately 5-30% of cases are familial. affected individuals are ascertained because of a failure to grow and short stature starting in infancy or early childhood. Patients with CPHD are associated with deficiencies of growth hormone (GH), thyroid-stimulating hormone (TSH), gonadotropins (luteinizing hormone (LH) and follicle-stimulating hormone (FSH)), and occasionally adrenocorticotrophic hormone (ACTH) (Otto et al. 2015. PubMed ID: 25315032). People with CPHD may have mild hypothyroidism which could cause poor weight gain and fatigue. Other features of CPHD include absent or delayed puberty and incomplete secondary sexual development with infertility, or more complex disorders such as septo-optic dysplasia (SOD) and holoprosencephaly. CPHD is caused by both genetic and nonheritable factors such as trauma, tumor, and infections. Approximately 50-60% of familial CPHD has a genetic basis and pathogenic variants in a number of different genes are found to cause genetically determined CPHD. The genes *GLI2*, *HESX1*, *LHX3*, *LHX4*, *OTX2*, *POU1F1*, *PROP1*, *SOX2*, and *SOX3* are the most studied ones. Of these, *PROP1* pathogenic variants are the most common known cause of this disorder, accounting for approximately 50% of familial cases, although the incidence in sporadic cases is much lower. These genes all encode transcription factors that are expressed in the developing head, hypothalamus, and/or pituitary, and have been involved in the proper development of the pituitary gland and the specialization of its cell types. Pathogenic variants in these genes perturb ontogenesis of pituitary gonadotropes, somatotropes, lactotropes, and thyrotropes. These developmental defects result in deficiencies of LH, which is needed for normal growth; FSH and GH, which both play a role in sexual development and fertility; TSH, which helps with thyroid gland function; and ACTH, which influences energy production in the body and maintains normal blood sugar and blood pressure levels. CPHD can be inherited in X-linked (*SOX3*), autosomal dominant (*GLI2*, *LHX4*, *HESX1*, *POU1F1*, *OTX2*, *SOX2*), or autosomal recessive (*HESX1*, *POU1F1*, *PROP1*, *LHX3*) manner.

## REGULATORY STATUS

### U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Approval or clearance by the Food and Drug Administration (FDA) does not in itself establish medical necessity or serve as a basis for coverage. Therefore, this section is provided for informational purposes only.

## CLINICAL EVIDENCE AND LITERATURE REVIEW

### EVIDENCE REVIEW

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding genetic testing for specific indications. Below is a summary of the available evidence identified through August 2023.

## **Hearing Loss**

Shearer and colleagues performed a meta-analysis in 2015 focusing on the current genetic tests used to evaluate hearing loss.<sup>7</sup> Twenty studies were included, containing 426 controls and 603 patients with idiopathic hearing loss. Several genetic panels such as OtoGenetics Deafness Test and OtoGenome were used. Overall, the controls showed good sensitivity and specificity (over 99%), and the diagnostic rate was found to be 41% (with a range of 10% – 83%). The authors concluded that “comprehensive genetic testing should form the cornerstone of a tiered approach to clinical evaluation of patients with hearing loss along with history, physical exam, and audiometry and can determine further testing that may be required, if any.”

In 2016, Sloan-Heggen and colleagues completed parallel sequencing on 1,119 “sequentially accrued” patients. 440 (39%) of these patients were found to have a genetic etiology for hearing loss.<sup>8</sup> Pathogenic variants were found in 49 genes, and various alterations such as missense variants (49% of the alterations), copy number variants (18%), insertions or deletions (13%), and nonsense variants (8%) were found. The authors noted the wide variety of the genetic spectrum of hearing loss.

### Unilateral:

In 2016, Sloan-Heggen and colleagues published a retrospective study on comprehensive genetic testing in patients with hearing loss.<sup>8</sup> There were 1119 patients, 69 of which had unilateral hearing loss. Patients with bilateral hearing loss were significantly more likely to receive a diagnosis than patients with asymmetric or unilateral hearing loss (44, 22 and 1 %, respectively;  $p < 0.005$ ).

In 2019 (updated in 2022), Hayes published a clinical utility evaluation on genetic testing in patients with or suspected of prelingual nonsyndromic hearing loss.<sup>9</sup> One study was identified that evaluated the clinical utility of genetic testing in this population, evaluating 209 patients and studying their psychological well-being pre and post testing. Hayes concluded that there was insufficient evidence to evaluate the clinical utility of genetic testing in patients with or suspected of prelingual nonsyndromic hearing loss.

## **Hypopituitarism**

According to Weizmann Institute of Science (MalaCards) and Medline Plus, 9 genes (GLI2, HESX1, LHX3, LHX4, OTX2, POU1F1, PROP1, SOX2, and SOX3) are most commonly associated with CPHD.<sup>10,11</sup>

According to Medline Plus:<sup>11</sup>

“Most cases of combined pituitary hormone deficiency are sporadic, which means they occur in people with no history of the disorder in their family. Less commonly, this condition has been found to run in families. When the disorder is familial, it can have an autosomal dominant or an autosomal recessive pattern of inheritance.”

## **CLINICAL PRACTICE GUIDELINES**

## Hearing Loss

### UpToDate

In 2022, UpToDate published guidelines on Hearing loss in children: Screening and evaluation.<sup>4</sup> They recommend the following:

“For patients with bilateral SNHL without syndromic findings, comprehensive genetic testing using NGS should be performed as the initial test [35].

The authors continue to discuss unilateral hearing loss: “For infants and children with bilateral SNHL, the evaluation typically includes comprehensive genetic testing of the patient and possibly other family members. By contrast, the yield of comprehensive genetic testing is low in children with unilateral SNHL in the absence of syndromic findings.”

“Unilateral SNHL – For children with unilateral SNHL, we suggest not routinely performing comprehensive genetic testing with NGS to evaluate for nonsyndromic hearing loss. The yield of NGS in this setting is low.

### Joint Commission on Infant Hearing (JCIH)

In 2007, the JCIH recommended that evaluation of infants with confirmed hearing loss should include a review of family history of specific genetic disorders or syndromes, including genetic testing for gene mutations such as GJB2 (connexin-26), and syndromes commonly associated with early-onset childhood sensorineural hearing loss.<sup>12</sup> In 2013, a supplement by the ASHA was added to the JCIH. The 2013 supplement also stated that medical providers must “understand atypical development etiologies and diagnoses, and refer for medical-genetic evaluation” and that families must be educated on the “importance of medical, genetic, ophthalmologic, and cardiac (EKG) evaluations on children with any type and degree of hearing loss”.

In 2019, the JCIH published an updated position statement.<sup>13</sup> They note that the American College of Medical Genetics and Genomics recommends offering genetic counseling and testing to all infants who are deaf or hard of hearing and their families. A geneticist’s evaluation should include “a review of family history of specific genetic disorders or syndromes, genetic testing for gene mutations such as GJB2 (connexin-26), and syndromes commonly associated with early-onset hearing loss”.

### International Pediatric Otolaryngology Group (IPOG)

In 2016, the IPOG released their guidelines on hearing loss in the pediatric patient.<sup>14</sup> Concerning which children should be offered comprehensive genetic testing they recommend the following:

“Comprehensive genetic testing should be offered to children with bilateral ANSD, or unilateral ANSD if imaging for cochlear nerve dysplasia is negative and no obvious acquired cause exists.”

“After an audiogram, comprehensive genetic testing has the highest diagnostic yield of any single test for bilateral sensorineural hearing loss.”



In addressing the question “Should single gene or directed genetic testing be used?”, they make the following consensus recommendation statements:

“In the setting of comprehensive genetic testing, single gene testing is of low diagnostic yield and should not be offered as part of an initial workup unless a known family history exists.”

“Directed genetic testing for GJB2/GJB6 should be considered if comprehensive genetic testing is unavailable.”

“Directed genetic testing may be considered in consultation with a geneticist if comprehensive genetic testing is negative but suspicion for a genetic cause still exists.”

### American Academy of Pediatrics (AAP)

The AAP also recommends genetic testing for evaluation of hearing loss.<sup>15</sup> Testing protocol typically tests GJB2/6 first, then applies targeted next generation sequencing of gene panels for recessive, dominant, x-linked patterns or syndromic hearing loss (AAP). AAP also notes that it is important to note that genetic testing “cannot identify 100% of genetic hearing loss; negative genetic testing does not rule out a genetic form of hearing loss.”

### **Hypopituitarism**

#### UpToDate

According to UpToDate’s 2022 guideline on Causes of Hypopituitarism: genes such as HESX1, LHX3, LHX4, and PROP1 have strong associations with CPHD, both sporadic and familial.<sup>16</sup>

“In addition to pituitary adenomas and their treatment (surgery or radiation therapy), other pituitary causes include... Mutations in genes that encode transcription factors, such as PROP-1, POU1F1, TPIT, HESX1, LHX3, and LHX4, that are important for differentiation of different pituitary cell types and/or pituitary organogenesis.”

No clinical guidelines were identified that find genetic testing clinically useful in determining treatment for CPHD and hypopituitarism.

### **EVIDENCE SUMMARY**

#### **Hearing Loss**

While studies continue to be elusive regarding specific information on comprehensive gene testing, several clinical practice guidelines continue to support this testing, particularly in patients with bilateral nonsyndromic hearing loss. There remains some conflicting reports regarding if comprehensive genetic testing should be completed during the initial test vs after single gene testing. However, the majority of the clinical practice guidelines support the comprehensive testing initially. The ACMG guideline which indicated single gene mutations should be considered first did indicate that comprehensive testing may be more cost effective. Testing for unilateral hearing loss is not recommended due to probable causes being frequently being structural in nature.

There is insufficient evidence to show that genetic panels have diagnostic utility for children with nonsyndromic unilateral hearing loss. Few studies were conducted on genetic testing for unilateral

hearing loss, and the limited data available suggests that large genetic panels have little diagnostic yield. Furthermore, clinical practice guidelines advise against the use of genetic panels for diagnosing unilateral hearing loss in nonsyndromic patients. Therefore, multi-gene genetic panel testing is considered not medically necessary in patients with nonsyndromic unilateral hearing loss.

### Hypopituitarism

Familial CPHD is uncommon, but it may affect family planning. Moreover, management requires a multi-disciplinary team approach to ensure adequacy of hormone replacement and evaluation of evolving hormone deficiencies. Genetic counselling should be offered to parents in whose infant a genetic cause has been identified. Therefore, genetic testing for CPHD in patients with hypopituitarism has some clinical utility and may be considered medically necessary.

## BILLING GUIDELINES AND CODING

Some, but not all genetic tests may have a specific CPT or HCPCS code assigned. Some panels may be billed with unlisted codes (e.g. 81479 or 81599) while others may be billed with multiple gene-specific and/or molecular pathology procedure codes (81400-81408).

| CODES* |       |   |
|--------|-------|---|
| CPT    |       |   |
|        | 0195U | KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)   |
|        | 0231U | CACNA1A (calcium voltage-gated channel subunit alpha 1A) (eg, spinocerebellar ataxia), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) gene expansions, mobile element insertions, and variants in non-uniquely mappable regions  |
|        | 0232U | CSTB (cystatin B) (eg, progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions |
|        | 0233U | FXN (frataxin) (eg, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions   |
|        | 0234U | MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions  |
|        | 0235U | PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions  |
|        | 0236U | SMN1 (survival of motor neuron 1, telomeric) and SMN2 (survival of motor neuron 2, centromeric) (eg, spinal muscular atrophy) full gene analysis,   |

|  |       |   |
|--|-------|---|
|  |       | including small sequence changes in exonic and intronic regions, duplications and deletions, and mobile element insertions  |
|  | 0237U | Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia), genomic sequence analysis panel including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions |
|  | 0238U | Oncology (Lynch syndrome), genomic DNA sequence analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions   |
|  | 0355U | APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)  |
|  | 81105 | Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P)   |
|  | 81106 | Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein Ib [platelet], alpha polypeptide [GPIba]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-2a/b (T145M)   |
|  | 81107 | Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-3a/b (I843S)   |
|  | 81108 | Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-4a/b (R143Q)  |
|  | 81109 | Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor] [GPIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant (eg, HPA-5a/b (K505E))  |
|  | 81110 | Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-6a/b (R489Q)   |
|  | 81111 | Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41] [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (V837M)  |
|  | 81112 | Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109 molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-15a/b (S682Y)   |
|  | 81120 | IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common variants (eg, R132H, R132C)   |

|       |   |
|-------|---|
| 81121 | IDH2 (isocitrate dehydrogenase 2 [NADP+], mitochondrial) (eg, glioma), common variants (eg, R140W, R172M)   |
| 81161 | DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed   |
| 81163 | BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis   |
| 81165 | BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis   |
| 81171 | AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles   |
| 81172 | AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)                           |
| 81173 | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence   |
| 81174 | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant   |
| 81175 | ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence                       |
| 81176 | ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12) |
| 81177 | ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles  |
| 81178 | ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles   |
| 81179 | ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles   |
| 81180 | ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles   |
| 81181 | ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles   |
| 81182 | ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles   |
| 81183 | ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles   |
| 81184 | CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles   |
| 81185 | CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence   |
| 81186 | CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant   |

|       |   |
|-------|---|
| 81187 | CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles   |
| 81188 | CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles   |
| 81189 | CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence   |
| 81190 | CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)  |
| 81200 | ASPA (aspartoacylase) (e.g., Canavan disease) gene analysis, common variants (e.g., E285A, Y231X)   |
| 81204 | AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)                |
| 81205 | BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (e.g., Maple syrup urine disease) gene analysis, common variants (e.g., R183P, G278s, E422X)   |
| 81209 | BLM (Bloom syndrome, RecQ helicase-like) (e.g., Bloom syndrome) gene analysis 2281 del6ins7 variant   |
| 81210 | BRAF(v-raf murine sarcoma viral oncogene homolog B1) (e.g. Colon Cancer) gene analysis, V600E variant   |
| 81219 | CALR (calreticulin)(eg myeloproliferative disorders, gene analysis, common variants in exon 9)  |
| 81233 | BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)  |
| 81234 | DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles   |
| 81235 | EGFR (Epidermal growth factor receptor)(EG, non-small cell lung cancer) gene analysis, common variants (EG, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)   |
| 81236 | EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence   |
| 81237 | EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)   |
| 81238 | F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence   |
| 81239 | DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)  |
| 81242 | FANCC (Fanconi anemia, complementation group C) (e.g., Fanconi Anemia, type C) gene analysis, common variant (e.g., IVS4=4A>T)  |
| 81243 | FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles                            |
| 81244 | FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis; characterization of alleles (eg, expanded size and promoter methylation status) |

|       |  |
|-------|--|
| 81247 | G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-)  |
| 81248 | G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)  |
| 81249 | G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence   |
| 81250 | G6PC (glucose-6-phosphatase, catalytic subunit) (e.g., Glycogen storage disease, type 1a, von Gierke disease) gene analysis, common variants (e.g., R83C, Q347X)   |
| 81251 | GBA (glucosidase, beta, acid) (e.g., Gaucher disease) gene analysis, common variants (e.g., N370S, 84GG, L444P, IVS2=1G>A)   |
| 81255 | HEXA (hexosaminidase A [alpha polypeptide]) (e.g. Tay-Sachs disease) gene analysis common variants (e.g., 1278insTATC, 1421+1G>C, G269S)   |
| 81256 | HFE (hemochromatosis) (e.g. hereditary hemochromatosis) gene analysis, common variants (e.g. C282Y, H63D)  |
| 81257 | HBA1/HBA2 (alpha globin 1 and alpha globin 2)(e.g. alpha thalassaemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (e.g., Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha20.5, and Constant Spring) |
| 81258 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassaemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant   |
| 81259 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassaemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequence   |
| 81260 | IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex- associated protein)(e.g. familial dysautonomia) gene analysis, common variants  |
| 81269 | HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassaemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variants  |
| 81271 | HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles  |
| 81274 | HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)   |
| 81275 | KRAS ((V-KI-RAS2 Kirsten Rat Sarcoma Viral Oncogene)( EG carcinoma) gene analysis, variants in codons 12 and 13  |
| 81276 | KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)   |
| 81284 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles   |
| 81285 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)  |
| 81286 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence   |
| 81289 | FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)  |
| 81290 | MCOLN1 (mucolipin 1 ) (e.g., Mucopolipidosis, Type IV) gene analysis, common variants (e.g. IVS3-2A>G, del6.4b)  |
| 81302 | MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis   |

|       |  |
|-------|--|
| 81303 | MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant   |
| 81304 | MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants 6 or exon 6), qualitative or quantitative  |
| 81305 | MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant   |
| 81311 | NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)   |
| 81312 | PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles  |
| 81315 | PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative         |
| 81316 | PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; single breakpoint (eg, intron 3, intron 6 or exon 6), qualitative or quantitative   |
| 81321 | PTEN (phosphatase and tensin)(e.g., Cowden Syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis  |
| 81322 | PTEN (phosphatase and tensin)(e.g., Cowden Syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant  |
| 81323 | PTEN (phosphatase and tensin)(e.g., Cowden Syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant  |
| 81324 | PMP22 (peripheral myelin protein 22)(e.g., Charcot-Marie-Tooth hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis  |
| 81325 | PMP22 (peripheral myelin protein 22)(e.g., Charcot-Marie-Tooth hereditary neuropathy with liability to pressure palsies) gene analysis; full sequence  |
| 81326 | PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth hereditary neuropathy with liability to pressure palsies) gene analysis; know familial variant   |
| 81327 | SEPT9 (Septin9) (eg, colorectal cancer) methylation analysis   |
| 81329 | SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed |
| 81330 | SMPD1 (sphingomyelin phosphodiesterase 1, acid lysosomal) (e.g., Niemann-Pick disease Type A) gene analysis, common variants (e.g., R496L, L302P, fsP330)  |
| 81331 | SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and Ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome methylation analysis  |
| 81332 | SERPINA 1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase variants (e.g., *S and *Z)  |
| 81333 | TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)   |



|       |  |
|-------|--|
| 81334 | RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (eg, exons 3-8)   |
| 81336 | SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence   |
| 81337 | SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)   |
| 81343 | PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles  |
| 81344 | TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles  |
| 81345 | TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)   |
| 81347 | SF3B1 (splicing factor [3b] subunit B1) (eg, myelodysplastic syndrome/acute myeloid leukemia) gene analysis, common variants (eg, A672T, E622D, L833F, R625C, R625L)   |
| 81348 | SRSF2 (serine and arginine-rich splicing factor 2) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, P95H, P95L)  |
| 81357 | U2AF1 (U2 small nuclear RNA auxiliary factor 1) (eg, myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (eg, S34F, S34Y, Q157R, Q157P)   |
| 81361 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); common variant(s) (eg, HbS, HbC, HbE)   |
| 81362 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s)   |
| 81363 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); duplication/deletion variant(s)   |
| 81364 | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); full gene sequence  |
| 81400 | Molecular pathology procedure, Level 1 (e.g., identification of single germline variant [e.g., SNP] by techniques such as restriction enzyme digestion or melt curve analysis)   |
| 81401 | Molecular pathology procedure, Level 2 (e.g., 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat)   |
| 81402 | Molecular pathology procedure, level 3 (e.g., >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants 1 exon) |
| 81403 | Molecular pathology procedure, level 4 (e.g. analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)                  |
| 81404 | Molecular pathology procedure, level 5 (e.g., analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10   |



|  |       |   |
|--|-------|---|
|  |       | exons, or characterization of a dynamic mutation disorder /triplet repeat by southern blot analysis   |
|  | 81405 | Molecular pathology procedure, level 6 (e.g., analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons)   |
|  | 81406 | Molecular pathology procedure, Level 7 (e.g., analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)  |
|  | 81407 | Molecular pathology procedure, level 8 (e.g., analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)   |
|  | 81408 | Molecular pathology, level 9 (e.g., analysis of >50 exons in a single gene by DNA sequence analysis)  |
|  | 81412 | Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1 |
|  | 81413 | Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, RYR2, and SCN5A                        |
|  | 81414 | Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1  |
|  | 81415 | Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis   |
|  | 81416 | Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)  |
|  | 81417 | Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)   |
|  | 81419 | Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2   |
|  | 81430 | Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1  |
|  | 81431 | Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes  |

|       |  |
|-------|--|
| 81434 | Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A   |
| 81437 | Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL   |
| 81438 | Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL  |
| 81439 | Hereditary cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes (eg, DSG2, MYBPC3, MYH7, PKP2, TTN)  |
| 81441 | Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2 |
| 81442 | Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1   |
| 81443 | Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucopolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)          |
| 81448 | Hereditary peripheral neuropathies (eg, Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (eg, BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1)   |
| 81479 | Unlisted Molecular Pathology   |
| 81595 | Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score  |
| 81599 | Unlisted multianalyte assay with algorithmic analysis  |

|       |       |   |
|-------|-------|---|
| HCPCS | S3870 | Comparative genomic hybridization (cgh) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability |
|-------|-------|---|

**\*Coding Notes:**

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- See the non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#) for additional information.
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

## REFERENCES

1. MedlinePlus. Nonsyndromic hearing loss. <https://medlineplus.gov/genetics/condition/nonsyndromic-hearing-loss/#:~:text=Collapse%20Section,classified%20in%20several%20different%20ways>. Accessed 7/24/2023.
2. Directors ABo. Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics. *Genet Med*. 2015;17(6):505-507.
3. Directors ABo. Points to consider in the clinical application of genomic sequencing. *Genet Med*. 2012;14(8):759-761.
4. UpToDate. Hearing loss in children: Screening and evaluation. [https://www.uptodate.com/contents/hearing-loss-in-children-screening-and-evaluation?topicRef=4985&source=see\\_link#H23](https://www.uptodate.com/contents/hearing-loss-in-children-screening-and-evaluation?topicRef=4985&source=see_link#H23). Published 2022. Accessed 7/20/2023.
5. UpToDate. Clinical manifestations of hypopituitarism. [https://www.uptodate.com/contents/clinical-manifestations-of-hypopituitarism?search=hypopituitarism&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/clinical-manifestations-of-hypopituitarism?search=hypopituitarism&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1). Published 2022. Accessed 7/24/2023.
6. Genetics. P. Combined Pituitary Hormone Deficiency (CPHD) Panel. [https://www.preventiongenetics.com/testInfo?val=Combined-Pituitary-Hormone-Deficiency-%28CPHD%29-Panel#:~:text=Combined%20pituitary%20hormone%20deficiency%20\(CPHD\)%20is%20a%20condition%20characterized%20by,are%20familial%20\(Ba%C3%85%C5%B8%20et%20al](https://www.preventiongenetics.com/testInfo?val=Combined-Pituitary-Hormone-Deficiency-%28CPHD%29-Panel#:~:text=Combined%20pituitary%20hormone%20deficiency%20(CPHD)%20is%20a%20condition%20characterized%20by,are%20familial%20(Ba%C3%85%C5%B8%20et%20al). Accessed 7/24/2023.
7. Shearer AE, Smith RJ. Massively Parallel Sequencing for Genetic Diagnosis of Hearing Loss: The New Standard of Care. *Otolaryngol Head Neck Surg*. 2015;153(2):175-182.
8. Sloan-Heggen CM, Bierer AO, Shearer AE, et al. Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss. *Hum Genet*. 2016;135(4):441-450.
9. Inc. H. Genetic Testing in Patients with or Suspected of Congenital and/or Prelingual Nonsyndromic Hearing Loss. Archived June 7, 2023.

- <https://evidence.hayesinc.com/report/gtu.hearingloss4631>. Published 2022. Accessed 7/24/2023.
10. Science Wlo. Combined Pituitary Hormone Deficiencies, Genetic Forms (CPHD1). Accessed 7/24/2023.
  11. MedlinePlus. Combined pituitary hormone deficiency. <https://medlineplus.gov/genetics/condition/combined-pituitary-hormone-deficiency/>. Accessed 7/24/2023.
  12. Joint Committee on Infant Hearing. Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. <https://publications.aap.org/pediatrics/article/120/4/898/71218/Year-2007-Position-Statement-Principles-and?autologincheck=redirected>. Published 2007. Accessed 7/20/2023.
  13. Joint Committee on Infant Hearing. Year 2019 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. <https://apps.asha.org/EvidenceMaps/Articles/ArticleSummary/28de0c07-7fed-4fe6-a2f8-f0472eb0ba16>. Published 2019. Accessed 7/20/2023.
  14. Liming BJ, Carter J, Cheng A, et al. International Pediatric Otolaryngology Group (IPOG) consensus recommendations: Hearing loss in the pediatric patient. *Int J Pediatr Otorhinolaryngol*. 2016;90:251-258.
  15. Ethical and policy issues in genetic testing and screening of children. *Pediatrics*. 2013;131(3):620-622.
  16. UpToDate. Causes of hypopituitarism. <https://www.uptodate.com/contents/causes-of-hypopituitarism>. Published 2023. Accessed 7/20/2023.

## POLICY REVISION HISTORY

| DATE    | REVISION SUMMARY   |
|---------|--|
| 2/2023  | Converted to new policy template.  |
| 6/2023  | Removed PA requirement for CPT 81256. Removed CPT 0049U to be placed on “Genetic Testing: Myeloproliferative Diseases” policy. |
| 7/2023  | Changed denial for criterion III. to “not medically necessary,”  |
| 11/2023 | Annual review. Expanded criteria to include specific tests with additional criteria.   |
| 1/2024  | Q1 2024 code set update. Code description revisions.   |